Sep 23, 2026
Oppenheimer Initiates Collegium Pharmaceutical at Outperform With $50 Price Target
Oppenheimer has initiated coverage on Collegium Pharmaceutical (COLL) with an Outperform rating and a $50 price target. This new rating is above the current average analyst rating of "buy" and mean price target of $48.86 for the company. The full details of this report require a premium subscription.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish